**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of Formula (1):




( 1 )

wherein:

Cy is a group of Formula (2):




( 2 )

$R_1$, $R_2$, $R_3$, $R_4$ and $R_5$ are hydrogen, halogen, or hydroxy and at least one of $R_1$, $R_2$, $R_3$, $R_4$ and $R_5$ is halogen;

$R_6$ is hydrogen;

$R_7$ is straight-chained or branched $C_{1-3}$alkyl, substituted with one or more hydroxyl groups, or amino optionally substituted with one or more straight-chained or branched $C_{1-3}$ alkyl groups which many be the same or different;

$R_8$ is hydrogen, methyl or ethyl;

$R_9$ is straight-chained or branched $C_{1-6}$ alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of phenyl, para-hydroxyphenyl, para-fluorophenyl, para-chlorophenyl, C3-7 cycloalkyl, halogen and thienyl, $C_{3-7}$cycloalkyl; or phenyl;

$R_{20}$ is hydrogen;

$R_{10}$ is hydrogen or methyl or ethyl ;

$R_{11}$ is straight-chained or branched $C_{1-3}$ alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino; hydroxyl, carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino and methanesulfonylamino, and -CO-$N(R_{14})R_{15}$;

$R_{12}$ is hydroxy;

$R_{13}$ straight-chained or branched $C_{1-6}$ alkyl[[,]];

$R_{14}$ and $R_{15}$, which may be the same or different, are each hydrogen, straight-chained or branched ~~$C_{1-3}$ alkyl~~ $C_{1-4}$ alkyl optionally substituted with hydroxyl or methanesulfonyl;, $C_{3-7}$cycloalkyl, straight-chained or branched $C_{1-4}$ alkoxy, straight-chained or branched $C_{1-4}$ alkylsulfonyl, or pyridyl;

~~$R_{18}$ and $R_{19}$ together form cycloalkyl or $C_{3-7}$ cycloalkenyl;~~

X is carbonyl or methylene;

Y is carbonyl;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2);

or a pharmaceutically acceptable salt thereof.

3. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which at least one of $R_1$, $R_2$, $R_3$, $R_4$ and $R_5$ is halogen and the others are hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

4. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which $R_3$ is halogen or $R_2$ and $R_3$ are the same kind of halogen;

or a pharmaceutically acceptable salt thereof.

5. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which $R_3$ is halogen and $R_1$, $R_2$, $R_4$ and $R_5$ are hydrogen, or $R_2$ and $R_3$ are the same kind of halogen and $R_1$, $R_4$ and $R_5$ are hydrogen; or a pharmaceutically acceptable salt thereof.

Claims 6-13. (Canceled)

14. (Previously presented) The compound according to claim 1, wherein $R_7$ in Formula (1) is hydrogen or amino optionally substituted with one or more of the same of different kinds of straight-chained or branched $C_{1-3}$ alkyl; or a pharmaceutically acceptable salt thereof.

15. (Previously presented) The compound according to claim 1, wherein $R_8$ in Formula (1) is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.

16. (Previously presented) The compound according to claim 1, wherein $R_9$ in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;
or a pharmaceutically acceptable salt thereof.

Claims 17-18. (Cancelled)

19. (Previously presented) The compound according to claim 1, wherein $R_{11}$ in Formula (1) is methyl,

hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,;
or a pharmaceutically acceptable salt thereof.

Claim 20 Cancelled

21. (Previously presented) The compound according to claim 1, wherein $R_{13}$ in Formula (1) is isopropyl, tert-butyl (tBu), or 1,1-dimethylpropyl;
or a pharmaceutically acceptable salt thereof.

22. (Previously presented) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of $R_1$, $R_2$, $R_3$, $R_4$ and $R_5$ is halogen and the others are hydrogen or hydroxy;
$R_8$ is hydrogen or methyl;
$R_9$ is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl phenyl;
$R_{11}$ is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl,

methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl;

$R_{13}$ is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl—or 1,1-dimethyl-2-propenyl;

or a pharmaceutically acceptable salt thereof.

23. (Previously presented) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Phe(3,4-$F_2$)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-

fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NH_2$, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NH_2$, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NH_2$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NH_2$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-

Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NH_2$, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NH_2$, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NH_2$, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val- N-Et-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2SO_2CH_3$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)- NHEt, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHiPr;

or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



( 4 )

wherein

Cy, $R_6$, $R_8$, $R_9$, $R_{20}$, $R_{10}$, $R_{12}$, $R_{13}$, X and Y are as defined in claim 1;

$R_7'$ is straight-chained or branched $C_{1-3}$alkyl substituted with one or more protected hydroxyl groups , or protected amino optionally substituted with one or more straight-chained or branched $C_{1-3}$ alkyl groups which may be the same or different; and

$R_{11}$" is straight-chained or branched $C_{1-3}$ alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino, hydroxyl[[;]], carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino, and methanesulfonylamino, and -CO-N($R_{14}$)$R_{15}$, wherein $R_{14}$ and $R_{15}$ are as defined in claim 1,[[;]]
or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A compound of Formula (5):




( 5 )

wherein:

Cy, $R_6$, $R_8$, $R_9$, $R_{20}$, $R_{10}$, $R_{12}$, $R_{13}$, X and Y are as defined in claim 1;

$R_7$" is straight-chained or branched $C_{1-3}$alkyl substituted with one or more optionally protected hydroxyl groups or amino optionally substituted with one or more different straight-chained or branched $C_{1-3}$ alkyl groups which may be the same or different; and

$R_{11}'$ is straight-chained or branched $C_{1-3}$alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of protected amino; protected hydroxyl, protected carbamoyl, protected ureide, protected guanidyl, protected N'-cyano-N"-methylguanidyl, protected sulfamoylamino, protected carbamoylmethylamino and protected methanesulfonylamino; $-CO-N(R_{14})R_{15}$ wherein $R_{14}$ and $R_{15}$ are those defined in claim 1 which are appropriately protected or a pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



( 6 )

wherein:

$R_8$ is hydrogen, methyl or ethyl;

$R_9$, is straight-chained or branched $C_{1-6}$ alkyl optionally substituted with one or more groups which may be the same or different ant are selected from the group consisting of phenyl, para-hydroxyphenyl, para-fluorophenyl, para-chlorophenyl, $C_{3-7}$ cycloalkyl, halogen and thienyl;

$R_{20}$ is hydrogen or methyl or;

$R_{10}$ is hydrogen or methyl or ethyl;

$R_{12}$ is hydroxy;

$R_{13}$ is straight-chained or branched $C_{1-6}$ alkyl; and

Y is carbonyl;

$P_1$ is hydrogen or a protecting group of amine; and

$R_{11}'''$ is straight-chained or branched $C_{1-3}$alkyl, carboxyl, straight-chained or branched $C_{1-3}$alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino hydroxyl, ~~methoxy, halogen,~~ carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino and methanesulfonylamino; straight-chained or branched $C_{1-3}$ alkyl having protected amino or and -CO-N($R_{14}$)$R_{15}$ wherein $R_{14}$ and $R_{15}$, which may be the same or different, are hydrogen, straight-chained or branched $C_{1-4}$ alkyl optionally substituted with hydroxy, $C_{3-7}$ cycloalkyl, straight-chained or branched $C_{1-4}$ alkoxy, straight-chained or branched $C_{1-4}$alkylsulfonyl, or pyridyl; or

a pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)

35. (Previously Presented) The compound according to claim 1, wherein the substitution of the optionally substituted straight-chained or branched $C_{1-3}$ alkyl as $R_7$ in formula (1) is halogen, hydroxyl or amino.